Sarepta Therapeutics, Inc. SRPT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s cash & equivalents?
- Sarepta Therapeutics, Inc. (SRPT) reported cash & equivalents of $464.45M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Sarepta Therapeutics, Inc.'s cash & equivalents increased by 92.8% year-over-year, from $240.87M to $464.45M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s cash & equivalents has grown at a -11.8% compound annual growth rate (CAGR), from $1.5B to $801.28M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.